GAITHERSBURG, Md. — February 4, 2026 — Leads & Copy — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) will launch a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design on March 25.
The new AI capability advances the Company’s end-to-end intelligence workflow by adding a strategic decision layer on top of existing platforms bfPREP™ and bfLEAP®.
According to BullFrog AI, the upcoming offering evaluates options using proprietary algorithms and methodologies revealing which programs are robust winners and which succeed only under narrow conditions, unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings.
Key capabilities include:
Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores
Tests portfolio decisions against multiple explicit scenarios (e.g., capital-constrained, platform-building, US-first, global)
Identifies options that perform well across strategic futures
Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation
BullFrog AI Founder and CEO Vin Singh said that life science and pharmaceutical companies spend more than $200 billion each year on research and development, with very low returns given an estimated 90% clinical trial failure rate.
Singh added that while AI adoption in drug discovery has accelerated, strategic portfolio decisions still rely largely on manual scoring and spreadsheet-based tools that force rigid rankings on fundamentally comparative judgments. He claims that the new capability takes a different approach by treating strategic scenarios as first-class inputs. It surfaces robust recommendations and highlights options that perform well under multiple strategic futures—enabling clear R&D strategies and the construction of diversified, risk-balanced R&D portfolios. According to Singh, to the company’s knowledge, no other solution in the world can offer this capability.
BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
Please visit the BullFrog AI website for updates on the new product launch.
Source: BullFrog AI
